Stacey A. Cohen

7.2k total citations
61 papers, 777 citations indexed

About

Stacey A. Cohen is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Stacey A. Cohen has authored 61 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 24 papers in Pathology and Forensic Medicine and 20 papers in Cancer Research. Recurrent topics in Stacey A. Cohen's work include Genetic factors in colorectal cancer (22 papers), Cancer Genomics and Diagnostics (18 papers) and Colorectal Cancer Treatments and Studies (15 papers). Stacey A. Cohen is often cited by papers focused on Genetic factors in colorectal cancer (22 papers), Cancer Genomics and Diagnostics (18 papers) and Colorectal Cancer Treatments and Studies (15 papers). Stacey A. Cohen collaborates with scholars based in United States, Greece and China. Stacey A. Cohen's co-authors include Alexey Aleshin, Minetta C. Liu, Polly A. Newcomb, Amanda I. Phipps, Sheetal Hardikar, Colin C. Pritchard, Gail P. Jarvik, Scott V. Adams, Andrea N. Burnett‐Hartman and Maresa C. Woodfield and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stacey A. Cohen

53 papers receiving 767 citations

Peers

Countries citing papers authored by Stacey A. Cohen

Since Specialization

Citations

This map shows the geographic impact of Stacey A. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacey A. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacey A. Cohen more than expected).

Fields of papers citing papers by Stacey A. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacey A. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacey A. Cohen. The network helps show where Stacey A. Cohen may publish in the future.

Co-authorship network of co-authors of Stacey A. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Stacey A. Cohen. A scholar is included among the top collaborators of Stacey A. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacey A. Cohen. Stacey A. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Potential Role of Circulating Tumor DNA as a Tool in the Management of Gastrointestinal Malignancies 2025 ·(unknown), Stacey A. Cohen	1
2	Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS / NRAS / BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer 2025 ·Ashwin Somasundaram, Dominic T. Moore, Anita Turk, Iman Imanirad, Stacey A. Cohen, Kristen K. Ciombor, (unknown), Autumn J. McRee, Michael S. Lee, Hanna K. Sanoff	1
3	Development of a methylation-based, tissue-agnostic test for the detection of molecular residual disease by circulating tumor DNA. 2025 ·Journal of Clinical Oncology ·John Paul Shen, Johannes G. Reiter, Joshua Babiarz, Preethi Srinivasan, (unknown), Ehsan Haghshenas, Tzu‐Chun Chen, Nathan L. Liang, Jayashree Joshi, Hsiao‐Yun Huang, (unknown), (unknown), Boris A. Gutman, Garima Kushwaha, Vasily N. Aushev, Marcia Cruz‐Correa, Matthew Rabinowitz, Trupti Kawli, (unknown), Stacey A. Cohen	1
4	Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal, and non-small cell lung cancers with KRAS G12V mutations. 2025 ·Journal of Clinical Oncology ·Rachael A. Safyan, Mary W. Redman, Andrew L. Coveler, Stacey A. Cohen, Sylvia Lee, Cecilia C.S. Yeung, Thomas M. Schmitt, Aude G. Chapuis, Philip D. Greenberg, E. Gabriela Chiorean	0
5	Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients 2024 ·International review of cell and molecular biology ·(unknown), (unknown), Jason J. Siu, Stacey A. Cohen	1
6	The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32. 2024 ·Journal of Clinical Oncology ·Hagen F. Kennecke, Christopher J. O’Callaghan, Dongsheng Tu, Roger Leung, Kristopher Dennis, Lisa A. Kachnic, Jonathan M. Loree, Mark H. Whiteford, (unknown), Stacey A. Cohen, Christopher Cann, Noam A. VanderWalde, Steven Nurkin, Therese Juul, Winson Y. Cheung, David P. Horowitz, (unknown), (unknown)	1
7	SWOG S1820: A pilot randomized trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer 2024 ·Cancer ·Virginia Sun, Katherine A. Guthrie, Tracy E. Crane, Kathryn B. Arnold, (unknown), (unknown), (unknown), (unknown), Craig Messick, Joseph C. Carmichael, (unknown), (unknown), Madhuri Bajaj, Stacey A. Cohen, Devin C. Flaherty, Mark Allen O’Rourke, Lee Jones, Robert S. Krouse, Cynthia A. Thomson	0
8	Abstract A003: Preliminary safety results from a phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T cell receptor (TCR) (FH-TCR TMSLN) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDA) 2024 ·Cancer Research ·E. Gabriela Chiorean, Aude G. Chapuis, Andrew L. Coveler, Cecilia C.S. Yeung, Ted Gooley, David B. Zhen, Gentry Teng King, Stacey A. Cohen, Lindsay M. Hannan, Rachael A. Safyan, (unknown), (unknown), (unknown), Thomas M. Schmitt, Philip D. Greenberg	0
9	Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations. 2024 ·Journal of Clinical Oncology ·Gentry Teng King, R J Berg, (unknown), Melissa C. Stoppler, Ronan W. Hsieh, Rachael A. Safyan, David B. Zhen, Andrew L. Coveler, Stacey A. Cohen, Veena Shankaran, E. Gabriela Chiorean, William Proctor Harris	1
10	Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery. 2024 ·Journal of Clinical Oncology ·Sakti Chakrabarti, Stacey A. Cohen, Antony Tin, (unknown), Vasily N. Aushev, Mohamedtaki Abdulaziz Tejani, Sreenivasa R Chandana, Midhun Malla, R. Landmann, Vivek R. Sharma, Gregory P. Botta, Arun Nagarajan, Georges Azzi, (unknown), Farshid Dayyani, Diana L. Hanna, Adham Jurdi, Minetta C. Liu, Arvind Dasari, Pashtoon Murtaza Kasi	1
11	Colorectal cancer pre-diagnostic symptoms are associated with anatomic cancer site 2024 ·BMC Gastroenterology ·(unknown), (unknown), (unknown), (unknown), Stacey A. Cohen, Amanda I. Phipps, Andrea N. Burnett‐Hartman, Polly A. Newcomb	4
12	Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer 2024 ·Current Oncology Reports ·(unknown), Stacey A. Cohen	5
13	114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers 2023 ·Annals of Oncology ·Gentry Teng King, Stacey A. Cohen, E. Gabriela Chiorean, William Proctor Harris, Raymond S. Yeung, (unknown), David B. Zhen, Andrew L. Coveler, Adam Diehl, Rachael A. Safyan, (unknown), (unknown)	4
14	Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas 2023 ·Cancer Epidemiology Biomarkers & Prevention ·Ming Yu, Kelly Carter, Kelsey K. Baker, Mary W. Redman, Ting Wang, (unknown), Christopher I. Li, Stacey A. Cohen, Mukta Krane, Jennifer Ose, Biljana Gigic, Jane C. Figueiredo, Adetunji T. Toriola, Erin M. Siegel, David Shibata, Martin Schneider, Cornelia M. Ulrich, (unknown), Robert E. Schoen, William M. Grady	3
15	Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. 2023 ·Journal of Clinical Oncology ·Stacey A. Cohen, Pashtoon Murtaza Kasi, Vasily N. Aushev, Diana L. Hanna, Gregory P. Botta, Saima Sharif, George Laliotis, Vivek R. Sharma, (unknown), Sreenivasa R Chandana, (unknown), Sakti Chakrabarti, Bradley G. Somer, Anup Kasi, Farshid Dayyani, Midhun Malla, Adham Jurdi, Minetta C. Liu, Alexey Aleshin, Scott Kopetz	11
16	Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer 2019 ·Advances in Radiation Oncology ·(unknown), Smith Apisarnthanarax, Stephanie K. Schaub, Stacey A. Cohen, (unknown), Wui-Jin Koh, Edward Y. Kim	8
17	Biomarker-driven and molecular targeted therapies for colorectal cancers 2017 ·Seminars in Oncology ·Marta Schirripa, Stacey A. Cohen, Francesca Battaglin, Heinz‐Josef Lenz	11
18	Cancer Stage in American Indians and Alaska Natives Enrolled in Medicaid 2016 ·American Journal of Preventive Medicine ·Scott V. Adams, Andrea N. Burnett‐Hartman, (unknown), Aasthaa Bansal, Stacey A. Cohen, Victoria Warren‐Mears, Scott D. Ramsey	6
19	Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin 2015 ·Clinical Colorectal Cancer ·Stacey A. Cohen, Chen Wu, Ming Yu, (unknown), (unknown), (unknown), (unknown), Vassiliki Kotoula, George Pentheroudakis, George Papaxoinis, Vasilios Karavasilis, Dimitrios Pectasides, Konstantine T. Kalogeras, George Fountzilas, William M. Grady	26
20	Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1. 2015 ·Gastroenterology report ·Janghee Woo, Stacey A. Cohen, Jonathan E. Grim	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact